Results 211 to 220 of about 6,459 (257)

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5787-5802, July 2026.
ABSTRACT Aims Young adults (aged ≤ 40 years) are underrepresented in clinical trials that investigate interventions for those living with Type 2 diabetes (T2D). This study evaluated the efficacy of semaglutide treatment in young adults with T2D by examining the effects on HbA1c and body weight (BW) during the SUSTAIN and PIONEER programmes compared to ...
Francesco Zaccardi, Vanita R. Aroda, Ecenur Guder Arslan, Lars Bardtrum, Jonathan Goldney, Erik Ising, Prachi Priyadarshini, Tommy Slater, Melanie J. Davies   +8 more
wiley   +1 more source

Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice. [PDF]

Sci Rep
Dan K, Sanada J, Kimura T, Iwamoto Y, Sugisaki T, Iwamoto H, Fushimi Y, Nogami Y, Shirakiya Y, Shimoda M, Nakanishi S, Kaku K, Kaneto H.   +12 more
europepmc   +1 more source

GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. [PDF]

Sci Prog
Gupta AK, Teasell EM, Economopoulos V, Mirmirani P.   +3 more
europepmc   +1 more source

Dietary Strategies and Nutritional Management in Patients Receiving GLP‐1 and Dual GIP/GLP‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5492-5507, July 2026.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual GIP/GLP‐1 RAs are widely used to manage obesity, prediabetes and type 2 diabetes, typically in combination with lifestyle interventions. Their nutritional implications, however, remain unclear.
Rayanne Santos de Paulo, Dandara Baia Bonifácio, Matheus Henrique Lana de Carvalho, Josefina Bressan   +3 more
wiley   +1 more source

Comparative Efficacy and Safety of Tirzepatide versus Semaglutide: A Systematic Review and Meta-Analysis with Cardiometabolic Implications. [PDF]

Nepal J Epidemiol
Baba AH, Akhtar R, Rawat A, Afzaal HB, Haq AU, Khalid MB, Ghazi MA, Awan J, Kumar P, Gurram YS, Khawar M.   +10 more
europepmc   +1 more source

Body Composition Optimization in the Era of GLP‐1‐Based Pharmacotherapy for Obesity Management

Lifestyle Medicine, Volume 7, Issue 3, July 2026.
Grant M. Tinsley, Spencer Nadolsky, Karl Nadolsky   +2 more
wiley   +1 more source

Acute onset of neovascular age-related macular degeneration after initiation of tirzepatide. [PDF]

Diabetol Int
Takebayashi K, Iemura Y, Yamauchi M, Hara K, Tsuchiya T, Machida S, Hashimoto K.   +6 more
europepmc   +1 more source

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6347-6357, July 2026.
ABSTRACT Aims Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort.
Anastasios Tentolouris, Charalampos Filippatos, Nikolaos‐Iason Tepetes, Maria Gavriatopoulou, Evangelos Terpos, Alexandros Briasoulis, Kimon Stamatelopoulos, Theodosios Filippatos   +7 more
wiley   +1 more source

Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates. [PDF]

Diabetes Ther
Rangraze IR, El-Tanani M, Janez A, Maggio V, Rabbani SA, Jensterle M, Munda A, Abbas EE, Ali HS, Farooqi MR, Patni MAF, Rizzo M.   +11 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms

Fundamental &Clinical Pharmacology, Volume 40, Issue 4, July 2026.
ABSTRACT Background Cocaine use disorder (CUD) remains a major public health concern, characterized by high relapse rates and the absence of approved pharmacological treatments. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), widely prescribed for metabolic disorders, modulate mesolimbic reward pathways and have been proposed as potential ...
Céline Eiden, Ghjulia Chautard, Anne Batisse, Aurélie Aquizerate, Amandine Luquiens, Hélène Donnadieu, Jean‐Luc Faillie, Hélène Peyriere   +7 more
wiley   +1 more source